Yttrium‐90 radioembolization‐induced abscopal effect on hepatocellular carcinoma

Steinhoff, Karen Geva; Petersen, Tim-Ole; Purz, Sandra; Veelken, Rhea; Boemmel, Florian van; Denecke, Timm; Berg, Thomas; Sabri, O.

doi:10.1111/1751-2980.13092

Cited by 4 publications

(4 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study showed that ablation could not only lead to local tumour destruction but also abscopal effects in distant lesions, which was most likely mediated by an antitumour immune response [ 11 ]. Another study showed that yttrium-90 radioembolization induced an abscopal effect on HCC [ 12 ]. In addition, nonthermal histotripsy tumour ablation promotes abscopal immune responses that enhance cancer immunotherapy [ 13 ].…”

Section: Discussionmentioning

confidence: 99%

Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases

Liu¹,

Xue²,

Bai³

et al. 2022

Heliyon

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases

Liu¹,

Xue²,

Bai³

et al. 2022

Heliyon

View full text Add to dashboard Cite

“…Key mechanisms proposed are the release of tumor antigens following radiation-induced cell death, in turn leading to activation of T cells systemically when presented by antigen-presenting cells. This implies the ability to target not only the irradiated tumor but also distant metastases, indicating this to be a hopeful strategy for HCC, which so far has poor prognosis and limited therapy [ 55 , 56 ]. This phenomenon underscores the synergistic potential of combining radiotherapy with immunotherapy, suggesting that radiotherapy may target the local tumor and induce systemic immune responses beneficial for overall treatment outcomes.…”

Section: Combination Of Radiotherapy and Immunotherapymentioning

confidence: 99%

Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma

Tojjari,

Yu,

Saeed

2024

Cancers

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC), a prevalent and often fatal liver cancer, presents significant treatment challenges, especially in its advanced stages. This article delves into the promising approach of combining immunotherapy, particularly immune checkpoint inhibitors, with radiation therapy, a cornerstone of HCC management. Our review synthesizes current preclinical and clinical research, highlighting the potential synergistic effects of this combinational treatment. Emerging evidence suggests that this synergy enhances tumor control and improves patient survival rates. The combination leverages the localized, tumor-targeting ability of radiation therapy and the systemic, immune-boosting effects of immunotherapy, potentially overcoming the limitations inherent in each treatment modality when used separately. This integrative approach is especially promising in addressing the complex tumor microenvironment of HCC. However, the treatment landscape is nuanced, with challenges such as patient-specific response variability and potential resistance to therapies. Future research directions should focus on refining these combination strategies, tailoring them to individual patient profiles, and understanding the underlying mechanisms that govern the interaction between immunotherapy and radiation therapy. Such advancements could significantly improve HCC management, setting new standards for patient care and treatment efficacy.

show abstract

Section: Reasons For Transarterial Internal Radiotherapymentioning

confidence: 99%

“…This unique anatomical structure allows for the transarterial delivery of therapeutic substances like radioactive microspheres. 9,10 Consequently, transarterial internal radiation therapy has emerged as a novel treatment for advanced hepatocellular carcinoma. 5 90 Y Selective Internal Radiation Therapy (SIRT) is a therapeutic procedure administered through the hepatic artery, allowing targeted delivery of high radiation doses to liver tumors.…”

Section: Reasons For Transarterial Internal Radiotherapymentioning

confidence: 99%

Applications of Yttrium-90 (90Y) in Hepatocellular Carcinoma

Jiang,

Yang,

Wang

2024

OTT

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) is the most common primary liver cancer, affecting millions of people worldwide. Due to the lack of systemic radiation therapy in hepatocellular carcinoma, researchers have been investigating the use of yttrium-90 ( 90 Y) radioembolization for local-regional tumor control since the 1960s. With the development of glass and resin 90 Y microspheres and the durable local control, good long-term efficacy, and equivalent tumor responsiveness and tolerability of 90 Y-selective internal irradiation compared with alternative therapies such as transarterial chemoembolization (TACE) and sorafenib, 90 Y radioembolization has gradually been applied in the treatment of hepatocellular carcinoma of all stages. In this article, we summarize the latest progress of 90 Y in the treatment of hepatocellular carcinoma in terms of its principle, advantages, indications, contraindications, efficacy and adverse effects.

show abstract

Yttrium‐90 radioembolization‐induced abscopal effect on hepatocellular carcinoma

Cited by 4 publications

References 8 publications

Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases

Spontaneous bacterial peritonitis in hepatocellular carcinoma after PD-1 inhibitor therapy: two clinical cases

Immunotherapy and Radiation Therapy Combinatorial Approaches in Hepatocellular Carcinoma

Applications of Yttrium-90 (90Y) in Hepatocellular Carcinoma

Contact Info

Product

Resources

About